|
Name |
Vermixocin A
|
| Molecular Formula | C21H24O6 | |
| IUPAC Name* |
6-hydroxy-2-(1-hydroxy-3-methylbutyl)-1-methoxy-8-methyl-10H-benzo[b][1,5]benzodioxocin-12-one
|
|
| SMILES |
CC1=CC2=C(C(=C1)O)OC3=C(C(=C(C=C3)C(CC(C)C)O)OC)C(=O)OC2
|
|
| InChI |
InChI=1S/C21H24O6/c1-11(2)7-15(22)14-5-6-17-18(20(14)25-4)21(24)26-10-13-8-12(3)9-16(23)19(13)27-17/h5-6,8-9,11,15,22-23H,7,10H2,1-4H3
|
|
| InChIKey |
UOWGLBYIKHMCIS-UHFFFAOYSA-N
|
|
| Synonyms |
Vermixocin A; 55303-92-9; 6-Hydroxy-2-(1-hydroxy-3-methylbutyl)-1-methoxy-8-methyl-10H-benzo[b][1,5]benzodioxocin-12-one; MLS000876835; MEGxm0_000100; CHEMBL1482850; ACon0_000965; ACon1_001043; HMS2271J09; NCGC00169730-03; SMR000440585; L008625; BRD-A46837972-001-01-0; 156966-02-8; NCGC00169730-03_C21H24O6_5H,7H-Dibenzo[b,g][1,5]dioxocin-5-one, 11-hydroxy-3-(1-hydroxy-3-methylbutyl)-4-methoxy-9-methyl-
|
|
| CAS | 156966-02-8 | |
| PubChem CID | 9842429 | |
| ChEMBL ID | CHEMBL1482850 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 372.4 | ALogp: | 3.7 |
| HBD: | 2 | HBA: | 6 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 85.2 | Aromatic Rings: | 3 |
| Heavy Atoms: | 27 | QED Weighted: | 0.749 |
| Caco-2 Permeability: | -4.97 | MDCK Permeability: | 0.00002050 |
| Pgp-inhibitor: | 0.014 | Pgp-substrate: | 0.011 |
| Human Intestinal Absorption (HIA): | 0.036 | 20% Bioavailability (F20%): | 0.006 |
| 30% Bioavailability (F30%): | 0.002 |
| Blood-Brain-Barrier Penetration (BBB): | 0.156 | Plasma Protein Binding (PPB): | 97.48% |
| Volume Distribution (VD): | 0.566 | Fu: | 3.27% |
| CYP1A2-inhibitor: | 0.85 | CYP1A2-substrate: | 0.849 |
| CYP2C19-inhibitor: | 0.888 | CYP2C19-substrate: | 0.526 |
| CYP2C9-inhibitor: | 0.747 | CYP2C9-substrate: | 0.877 |
| CYP2D6-inhibitor: | 0.543 | CYP2D6-substrate: | 0.562 |
| CYP3A4-inhibitor: | 0.424 | CYP3A4-substrate: | 0.468 |
| Clearance (CL): | 11.895 | Half-life (T1/2): | 0.494 |
| hERG Blockers: | 0.027 | Human Hepatotoxicity (H-HT): | 0.016 |
| Drug-inuced Liver Injury (DILI): | 0.178 | AMES Toxicity: | 0.331 |
| Rat Oral Acute Toxicity: | 0.708 | Maximum Recommended Daily Dose: | 0.931 |
| Skin Sensitization: | 0.791 | Carcinogencity: | 0.857 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.705 |
| Respiratory Toxicity: | 0.521 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000877 | ![]() |
1.000 | D04UTT | ![]() |
0.310 | ||
| ENC004018 | ![]() |
0.805 | D0L1JW | ![]() |
0.294 | ||
| ENC002005 | ![]() |
0.773 | D06GCK | ![]() |
0.288 | ||
| ENC002739 | ![]() |
0.724 | D06GIP | ![]() |
0.288 | ||
| ENC002740 | ![]() |
0.724 | D07MGA | ![]() |
0.286 | ||
| ENC006148 | ![]() |
0.724 | D04TDQ | ![]() |
0.282 | ||
| ENC004016 | ![]() |
0.721 | D02FCQ | ![]() |
0.277 | ||
| ENC004017 | ![]() |
0.682 | D0Z1WA | ![]() |
0.272 | ||
| ENC006147 | ![]() |
0.644 | D03DJL | ![]() |
0.268 | ||
| ENC003674 | ![]() |
0.625 | D02LZB | ![]() |
0.263 | ||